These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 36436175)
21. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities. Carpi M; Palagini L; Fernandes M; Calvello C; Geoffroy PA; Miniati M; Pini S; Gemignani A; Mercuri NB; Liguori C Neuropharmacology; 2024 Mar; 245():109815. PubMed ID: 38114045 [TBL] [Abstract][Full Text] [Related]
22. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547 [TBL] [Abstract][Full Text] [Related]
23. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia. Ziemichód W; Grabowska K; Kurowska A; Biała G Molecules; 2022 Sep; 27(18):. PubMed ID: 36144776 [TBL] [Abstract][Full Text] [Related]
24. Role of the orexin system in the bidirectional relation between sleep and epilepsy: New chances for patients with epilepsy by the antagonism to orexin receptors? Berteotti C; Calvello C; Liguori C Epilepsia; 2023 Aug; 64(8):1991-2005. PubMed ID: 37212716 [TBL] [Abstract][Full Text] [Related]
25. Characteristics of Seltorexant-Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety. Ziemichód W; Kurowska A; Grabowska K; Kurowska M; Biała G Molecules; 2023 Apr; 28(8):. PubMed ID: 37110810 [TBL] [Abstract][Full Text] [Related]
26. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676 [TBL] [Abstract][Full Text] [Related]
27. Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis. Rocha RB; Bomtempo FF; Nager GB; Cenci GI; Telles JPM Arq Neuropsiquiatr; 2023 May; 81(5):475-483. PubMed ID: 37257468 [TBL] [Abstract][Full Text] [Related]
28. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Roch C; Bergamini G; Steiner MA; Clozel M Psychopharmacology (Berl); 2021 Oct; 238(10):2693-2708. PubMed ID: 34415378 [TBL] [Abstract][Full Text] [Related]
29. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Clark JW; Brian ML; Drummond SPA; Hoyer D; Jacobson LH Sleep Med Rev; 2020 Oct; 53():101332. PubMed ID: 32505969 [TBL] [Abstract][Full Text] [Related]
30. Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review. Besterman AD; Jeste SS Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):527-531. PubMed ID: 34611728 [TBL] [Abstract][Full Text] [Related]
31. Therapeutics development for addiction: Orexin-1 receptor antagonists. Perrey DA; Zhang Y Brain Res; 2020 Mar; 1731():145922. PubMed ID: 30148984 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain. McDonald T; Liang HA; Sanoja R; Gotter AL; Kuduk SD; Coleman PJ; Smith KM; Winrow CJ; Renger JJ J Neurogenet; 2016 Mar; 30(1):32-41. PubMed ID: 27276194 [TBL] [Abstract][Full Text] [Related]
33. Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant. Jha MK Int J Neuropsychopharmacol; 2022 Jan; 25(1):85-88. PubMed ID: 34791262 [TBL] [Abstract][Full Text] [Related]
36. Dual Orexin Receptor Antagonists (DORAs) as an Adjunct Treatment for Smoking Cessation. Hamidovic A CNS Drugs; 2022 May; 36(5):411-417. PubMed ID: 35451800 [TBL] [Abstract][Full Text] [Related]
37. Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment. Palagini L; Geoffroy PA; Balestrieri M; Miniati M; Biggio G; Liguori C; Menicucci D; Ferini-Strambi L; Nobili L; Riemann D; Gemignani A J Sleep Res; 2023 Aug; 32(4):e13825. PubMed ID: 36786121 [TBL] [Abstract][Full Text] [Related]
38. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice. Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365 [TBL] [Abstract][Full Text] [Related]
39. Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. Connor KM; Ceesay P; Hutzelmann J; Snavely D; Krystal AD; Trivedi MH; Thase M; Lines C; Herring WJ; Michelson D Int J Neuropsychopharmacol; 2017 Aug; 20(8):613-618. PubMed ID: 28582570 [TBL] [Abstract][Full Text] [Related]
40. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia. Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]